Viridian Therapeutics, Inc.\DE (VRDN) EBITDA (2013 - 2026)

Viridian Therapeutics, Inc.\DE's EBITDA history runs 14 years deep, the most recent figure standing at -$116.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 23.76% year-over-year to -$116.2 million; the TTM figure through Mar 2026 stood at -$385.7 million (down 14.45% YoY), while the FY2025 annual figure was -$363.4 million, down 21.52% from the prior year.
• EBITDA for Q1 2026 stood at -$116.2 million, up from -$122.7 million in the prior quarter.
• The five-year high for EBITDA was -$25.9 million in Q1 2022, with the low at -$122.7 million in Q4 2025.
• The 5-year median for EBITDA is -$71.5 million (2023), against an average of -$68.7 million.
• The sharpest annual moves came in 2023 and 2025: EBITDA plunged 179.94% in 2023, then surged 52.07% in 2025.
• Viridian Therapeutics, Inc.\DE's EBITDA stood at -$49.1 million in 2022, then tumbled by 45.68% to -$71.5 million in 2023, then slipped by 22.38% to -$87.5 million in 2024, then slumped by 40.33% to -$122.7 million in 2025, then climbed by 5.36% to -$116.2 million in 2026.
• Business Quant data shows VRDN's EBITDA at -$116.2 million in Q1 2026, -$122.7 million in Q4 2025, and -$40.0 million in Q3 2025.